Track topics on Twitter Track topics that are important to you
Spanish venture firm Ysios Capital Partners closed its second fund, Ysios BioFund II Innvierte, with EUR 126.4 million ($138.7 million). The raise was above its EUR 100 million ($109.8 million) target (see BioCentury Extra, March 29, 2014).
Ysios intends to invest in up to 15 early and development stage companies, primarily in Spain. Investors in the new fund included Spain's Centro para el Desarrollo Tecnologico Industrial (CDTI); the European Investment Fund (EIF) and the European Commission via InnovFin SME Venture Capital, part of the EU's Horizon 2020 strategy; pension funds including Orza and Lagun Aro; Banc Sabadell (BIDSA) and undisclosed private investors.
The fund already has invested in Laboratoris Sanifit S.L. (Palma de Mallorca, Spain), Minoryx Therapeutics S.L. (Mataro, Spain), Aelix Therapeutics S.L. (Barcelona, Spain), Prexton Therapeutics S.A. (Plan les Outes, Switzerland) and Aura Biosciences Inc. (Cambridge, Mass.).
Original Article: Ysios closes EUR 126.4M fundNEXT ARTICLE